Amy Lee
Analyst, Jefferies
Replay available
Liquidia Corporation (NASDAQ: LQDA) Q3 2025 earnings conference call, held 2025-11-03. Replay captured from the company's public earnings webcast.

Analyst, Jefferies
General Counsel
Chief Operating Officer & Chief Financial Officer
Chief Business Officer
Chief Medical Officer
Analyst, Bank of America
Analyst, BTIG
Analyst, LifeSci Capital
Watch the replay and follow the connected company analysis, news, and investor updates for Liquidia Corporation.
WEBVTT 00:00:00.031 -- 00:00:05.359 Good morning, and welcome to the Liquidia Corporation third quarter 2025 00:00:05.359 -- 00:00:09.905 financial results and corporate update conference call. 00:00:09.905 -- 00:00:12.870 My name is Carmen, and I will be your operator today. 00:00:12.870 -- 00:00:16.875 All participants are current in analysis-only mode. 00:00:16.875 -- 00:00:21.602 Following the presentation, we will conduct a question and answer session. 00:00:21.602 -- 00:00:26.309 Instructions for joining the queue will be provided at that time. 00:00:26.309 -- 00:00:29.883 Please note that today's call is being recorded. 00:00:29.883 -- 00:00:35.869 I now turn the call over to Jason Adair, Chief Business Officer. 00:00:36.773 -- 00:00:38.836 Thank you, Carmen, and good morning, everyone. 00:00:38.836 -- 00:00:43.283 It's my pleasure to welcome you to Liquidia's third quarter 2025 financial results and 00:00:43.283 -- 00:00:46.788 corporate update conference call. Joining me today are Dr. 00:00:46.788 -- 00:00:51.395 Roger Jeff, Chief Executive Officer, Michael Cassetta, Chief Operating Officer and Chief 00:00:51.395 -- 00:00:56.563 Financial Officer, Dr. Rajiv Sagar, Chief Medical Officer, Scott Mummo, Chief 00:00:56.563 -- 00:01:00.207 Commercial Officer, and Rusty Schundler, General Counsel. 00:01:00.207 -- 00:01:04.632 Before we begin, please note that today's discussion will include forward-looking statements, 00:01:04.632 -- 00:01:08.998 including statements regarding future results, product performance, and ongoing clinical 00:01:08.998 -- 00:01:13.323 or commercial activity. These statements are subject to risks and uncertainties that 00:01:13.323 -- 00:01:16.727 may cause actual results to differ materially. 00:01:16.727 -- 00:01:22.234 For further info...